H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter“Fujirebio”) today announced that ...

As Live Biotherapeutic Products (LBPs) begin to transition from frontier science to clinical reality, Novotech, a leading global CRO and scientific advisory partner has published a new white paper ...

The global Biosimilars Market, valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to ...

Indian pharma grapples headwinds of US pricing reform & Europe’s HTA-driven cost-effectiveness: Akash Kedia: Nandita Vijayasimha, Bengaluru Monday, June 9, 2025, 08:00 Hrs [IST] ...

Adjusted EPS: $1.31 vs analyst estimates of $1.26 (3.6% beat) ・Adjusted Operating Income: $419 million vs analyst estimates of $409.9 million (25.1% margin, 2.2% beat) ・Revenue Guidance for Q2 CY2025 ...

Whether you're navigating capacity planning, considering a CDMO partnership, or tracking innovation in manufacturing, this conversation offers valuable insights into where the market is headed. 1.

The CDMO landscape is changing, influenced by the evolving needs of biotech companies. A notable trend is the growing preference among biotechs for partnering with smaller, more specialized CDMOs.

1.1.10 Current Nucleic Acid Therapeutics CDMO Landscape 1.1.11 Significant Usage of Nucleic Acid Therapeutics 1.1.12 Types of Nucleic Acid Synthesized for Therapeutics 1.1.12.1 Anti-sense ...

The global pharmaceutical CDMO market. size to rise from USD 156.62 billion in 2024 is to capture around USD 315.08 billion by 2034, expanding at a compound annual growth rate ... Competitive ...